Ruxotemitide

Summary

Ruxotemitide (LTX-109) is a synthetic cationic peptidomimetic developed by Lytone Pharma (originally Epitarget/Lytix Biopharma) for the topical treatment of bacterial skin infections, including impetigo and nasal decolonization of Staphylococcus aureus (including MRSA). It exhibits broad-spectrum antimicrobial activity through direct membrane disruption and innate immune modulation.

Mechanism of Action

Ruxotemitide (LTX-109) is a synthetic antimicrobial peptidomimetic that acts as a membrane-disrupting agent with direct bactericidal activity and also stimulates innate immune responses via TLR2 activation, disrupting bacterial cell membranes and modulating local immune defense.

Routes of Administration

Goals & Uses

• Innate immune modulationImmunologyLow
• Treatment of skin and soft tissue infections (SSTIs)Antibacterial / DermatologyLow
• Treatment of impetigoDermatology / Anti InfectiveModerate
• Nasal decolonization of MRSAAntibacterial / Infection PreventionModerate

Contraindications

• Application to open wounds or mucous membranes not indicatedAdministration SafetyModerate
• Known hypersensitivity to ruxotemitide or excipientsAllergyHigh

Adverse Effects

• Contact dermatitisDermatologicalUncommon
• Application site painLocalCommon
• Application site irritationLocal/dermatologicalCommon
• Nasal discomfortLocal/mucosalCommon

Drug Interactions

• Other topical antimicrobials (e.g., mupirocin)Low

Population Constraints

• Immunocompromised patientsImmunologicRelative
• Pregnant womenReproductiveRelative
• Pediatric patients (<2 years)AgeRelative

Regulatory Status

• European UnionInvestigationalClinical trials conducted in Europe; no EMA approval as of knowledge cutoff.
• United StatesInvestigationalFDA QIDP and Fast Track designation granted for impetigo; not yet approved. Phase 2/3 studies completed.
• United KingdomInvestigationalNo MHRA approval; investigational status.

Ruxotemitide has received Qualified Infectious Disease Product (QIDP) designation and Fast Track designation from the FDA for treatment of impetigo. It is not yet approved in any jurisdiction. Phase 2/3 clinical trials have been conducted for impetigo and nasal MRSA decolonization.

Evidence & Sources

No sources recorded yet.